Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets: 2021-2025

Historic Other Non-Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $8.3 million.

  • Kiniksa Pharmaceuticals International's Other Non-Current Assets rose 5.54% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 5.54%. This contributed to the annual value of $10.3 million for FY2024, which is 1147.28% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Other Non-Current Assets stood at $8.3 million for Q3 2025, which was up 1.13% from $8.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Other Non-Current Assets high stood at $10.3 million for Q4 2024, and its period low was $827,000 during Q4 2023.
  • Its 3-year average for Other Non-Current Assets is $5.7 million, with a median of $7.9 million in 2024.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Other Non-Current Assets tumbled by 85.80% in 2023, and later skyrocketed by 1,147.28% in 2024.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Other Non-Current Assets stood at $8.7 million in 2021, then crashed by 33.21% to $5.8 million in 2022, then tumbled by 85.80% to $827,000 in 2023, then skyrocketed by 1,147.28% to $10.3 million in 2024, then increased by 5.54% to $8.3 million in 2025.
  • Its Other Non-Current Assets stands at $8.3 million for Q3 2025, versus $8.2 million for Q2 2025 and $8.2 million for Q1 2025.